Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shingles vaccine shows promise in Head-to-Head trial

NCT ID NCT06581575

First seen May 07, 2026 · Last updated May 23, 2026 · Updated 3 times

Summary

This study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. About 467 participants will receive either JCXH-105 or the current vaccine Shingrix to compare safety and immune response. The goal is to see if the new vaccine can prevent shingles as well or better than the existing option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SHINGLES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • DM Clinical Research - Chicago

    Chicago, Illinois, 60652, United States

  • DM Clinical Research - New Jersey

    Jersey City, New Jersey, 07306, United States

  • DM Clinical Research - Sugarland

    Sugar Land, Texas, 77478, United States

  • Delricht Research

    Charleston, South Carolina, 29407, United States

  • Delricht Research

    Prosper, Texas, 75078, United States

  • Long Beach Research Institute

    Long Beach, California, 90805, United States

  • Noble Clinical Research

    Tucson, Arizona, 85704, United States

  • Quality Clinical Research

    Omaha, Nebraska, 68114, United States

Conditions

Explore the condition pages connected to this study.